Biomerica’s QQ1 2026 results show a small top-line expansion on a trailing basis but continued negative operating leverage at the reported quarter level. Revenue for QQ1 2026 was 1.38 million USD, with gross profit of 424 thousand USD (gross margin ~30.7%), and an operating loss of 1.118 million USD. EBITDA stood at 107 thousand USD, while net income was essentially flat at 2 thousand USD for the quarter, yielding a net margin of roughly 0.15%. The quarter benefited from a non-operating uplift of 1.123 million USD from other income/expenses, but core operating performance remained negative, underscoring limited scale and ongoing fixed cost absorption. Cash flow from operations was negative at 268 thousand USD, driven by working capital pressure (net outflow ~550 thousand USD) and non-cash items such as stock-based compensation (460 thousand USD). Financing activities provided a meaningful offset (net cash from financing of 920 thousand USD) via common stock issuances, lifting the cash balance to about 3.02 million USD at period end. The balance sheet remains liquid with a strong current ratio (~3.48) and minimal debt (total debt of ~373 thousand USD, net debt negative by ~2.68 million USD), supporting a cautious but constructive investment stance given the company’s strategic focus on GI diagnostics and InFoods-related therapies. Management commentary is not reflected in the provided transcript data; where available, the implications center on leveraging the InFoods and diagnostics pipeline to achieve scale, while navigating expense structure and the need for external financing to fund operations.